Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dotinurad - Fuji Yakuhin/Mochida Pharmaceutical

Next Previous
Drug Profile

Dotinurad - Fuji Yakuhin/Mochida Pharmaceutical

Alternative Names: FYU-981; URECE; Urece; Yurisu

Latest Information Update: 14 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fuji Yakuhin
  • Developer Crystalys Therapeutics; Eisai Co Ltd; Fuji Yakuhin; Mochida Pharmaceutical
  • Class Antigouts; Benzothiazoles; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout; Hyperuricaemia

Most Recent Events

  • 13 Aug 2025 Phase-III clinical trials in Gout in USA (PO) (NCT07089875)
  • 04 Aug 2025 Crystalys Therapeutics initiates a phase III trial in Gout in the US (PO) (NCT07089888)
  • 30 Jul 2025 Crystalys Therapeutics plans a phase-III trial for Gout (In adults, In the elderly) (PO, Tablet) (EUCT2024-520207-84-00) (NCT07089888)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top